Global Cancer Immunotherapies Market to 2024 - Increased Uptake of Immune Checkpoint Inhibitors Driving Growth, Supported by a Large, Robust Pipeline
Summary
Cancer immunotherapy, which can predominantly be classed as a form of targeted therapy, drives an immune response against cancer cells. This may include stimulating a patient's immune system in a general way or aiding the identification of specific antigens associated with the cancer.
The interest in cancer immunotherapy development has been driven by the growing understanding of the immune system as a hallmark of cancer pathophysiology, particularly immune evasion of developing cancer cells. Overall, 3,863 products are being actively developed in the cancer immunotherapy pipeline, approximately half of the overall oncology pipeline.
The report focuses on the key indications of breast cancer, leukemia, lymphoma, melanoma and non-small cell lung cancer, these indications are the largest in terms of size, with 448, 526, 456, 415 and 374 in active development, respectively. The pipeline is dominated mAbs, cell therapies, small molecules and cancer vaccines.
Scope
- Global revenue from the cancer immunotherapies market is forecast to increase from $33.7 billion in 2017 to $103.4 billion in 2024, at a compound annual growth rate of 17.4%. What is driving this growth?
- The leading companies in terms of market share are Celgene, Merck & Co., Bristol-Myers Squibb and Roche. Which of these are forecast to experience the largest growth?
- There are some key new approvals and late-stage products set to enter the market during the forecast period. Which impact will these drugs have on the market?
- The market has been dominated by immune checkpoint inhibitors and drugs that target tumor associated antigens. To what extent will these classes of drugs and others dominate the market over the forecast period?
- There are 3,863 cancer immunotherapy products in the pipeline. What molecular targets are most abundant in the pipeline and what role will pipeline product approvals play in market growth?
- Cancer immunotherapy clinical trials have an overall attrition rate of around 96%, what can companies do to maximize their chance of success?
Reasons to buy
- Understand the current treatment landscape, with portfolios of key marketed products and a focus on historical and forecast sales patterns, and an overview of each drug's mechanism of action.
- Analyze the cancer immunotherapy pipeline through a comprehensive review of the pipeline segmented by stage of development, molecule type and molecular target. This review also provides a detailed look at current cancer immunotherapies to provide an insight into the risk associated of attempting to bring pipeline products to market.
- Predict growth in market size, with in-depth market forecasting from 2017 to 2024. The forecasts will provide an understanding of how epidemiology trends, new drug entries, and certain patent expirations will influence market value.
- Identify commercial opportunities in the cancer immunotherapies deals landscape by analyzing trends in licensing and co-development deals
Global Cancer Immunotherapies Market to 2024 - Increased Uptake of Immune Checkpoint Inhibitors Driving Growth, Supported by a Large, Robust Pipeline
1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 7
2 Introduction 12
2.1 Therapy Area Introduction 12
2.2 Overview of Key Indications and Symptoms 12
2.2.1 Breast Cancer 13
2.2.2 Leukemia 15
2.2.3 Lymphoma 15
2.2.4 Melanoma 16
2.2.5 Non-Small Cell Lung Cancer 17
2.3 Diagnosis 18
2.3.1 Breast Cancer 18
2.3.2 Leukemia 18
2.3.3 Lymphoma 19
2.3.4 Melanoma 20
2.3.5 Non-Small Cell Lung Cancer 22
2.4 Etiology and Pathophysiology 23
2.4.1 Breast Cancer 26
2.4.2 Leukemia 27
2.4.3 Lymphoma 29
2.4.4 Melanoma 32
2.4.5 Non-Small Cell Lung Cancer 33
2.5 Epidemiology 37
2.5.1 Breast Cancer 38
2.5.2 Leukemia 38
2.5.3 Lymphoma 39
2.5.4 Melanoma 40
2.5.5 Non-Small Cell Lung Cancer 41
2.6 Prognosis 42
2.6.1 Breast Cancer 42
2.6.2 Leukemia 43
2.6.3 Lymphoma 44
2.6.4 Melanoma 44
2.6.5 Non-Small Cell Lung Cancer 45
2.7 Treatment 46
3 Key Marketed Products 49
3.1 Overview 49
3.2 Revlimid (lenalidomide) - Celgene 50
3.3 Opdivo (nivolumab) - Ono Pharma/Bristol-Myers Squibb 53
3.4 Keytruda (pembrolizumab) - Merck & Co. 55
3.5 Tecentriq (atezolizumab) - Roche 57
3.6 Darzalex (daratumumab) - Johnson & Johnson 59
3.7 Imfinzi (durvalumab) - AstraZeneca/Celgene 60
3.8 Gardasil/Gardasil 9 (human papillomavirus vaccine) - Merck & Co. 62
3.9 Pomalyst/Imnovid (pomalidomide) - Celgene 65
3.10 Yescarta (axicabtagene ciloleucel) - Gilead Sciences 66
3.11 Gazyva (obinutuzumab) - Roche 68
3.12 Yervoy (ipilimumab) - Bristol-Myers Squibb 69
3.13 Rituxan (rituximab) - Roche/Biogen 71
3.14 Kymriah (tisagenlecleucel) - Novartis 73
4 Pipeline Landscape Assessment 76
4.1 Overview 76
4.2 Pipeline Development Landscape 76
4.3 Molecular Targets in the Pipeline 79
4.4 Clinical Trials Landscape 82
4.4.1 Clinical Trial Failure Rates 83
4.4.2 Clinical Trial Duration 87
4.4.3 Clinical Trial Size 91
4.4.4 Cumulative Clinical Trial Size 94
4.5 Late-Stage Drugs of the Developmental Pipeline 99
4.5.1 Lisocabtagene maraleucel - Juno Therapeutics/Celgene 99
4.5.2 Durvalumab plus Tremelimumab - AstraZeneca 100
4.5.3 Tremelimumab - AstraZeneca 101
4.5.4 Cemiplimab - Regeneron/Sanofi 103
4.5.5 Epacadostat - Incyte Corp 104
4.5.6 Axalimogene filolisbac - Advaxis 106
5 Multi-scenario Market Forecast to 2024 108
5.1 Overall Market Size 108
5.2 Generic Penetration 112
5.3 Revenue Forecast by Molecular Target 113
5.3.1 Immune Checkpoint Proteins 114
5.3.2 Tumor Associated Antigens 114
5.3.3 Cytokine Signaling 117
5.3.4 HPV 118
6 Company Analysis and Positioning 119
6.1 Revenue and Market Share Analysis by Company 120
6.1.1 Celgene - Revlimid to Maintain Celgene's Position as Market Leader 124
6.1.2 Merck & Co. - Keytruda Key to Cancer Immunotherapy Market Growth 126
6.1.3 Bristol-Myers Squibb - Opdivo to Drive Revenue from Cancer Immunotherapies 127
6.1.4 Roche - Strong Revenue from Tecentriq and Gazyva Set to Offset Loss from Rituxan 127
6.1.5 AstraZeneca - Revenue from Imfinzi set to Drive Growth amid Growing Immunotherapy Presence 128
6.1.6 Johnson & Johnson - Darzalex Key to Strong Growth 130
6.1.7 Novartis - Diverse Cancer Immunotherapies Portfolio Contributes Small Portion to Overall Revenue 131
6.1.8 AbbVie - Recent New Approvals to Result in AbbVie Becoming a Leading Player in 2024 132
6.1.9 Gilead Sciences - Growth Driven by CAR-T Therapy Yescarta 133
6.1.10 Amgen - Rituximab Biosimilar to Drive Growth for Amgen in a Portfolio with No Novel Blockbusters 134
6.2 Market and Pipeline Company Landscape 134
7 Strategic Consolidations 138
7.1 Licensing Deals 138
7.1.1 Deals by Region, Deal Value and Year 138
7.1.2 Deals by Indication and Deal Value 140
7.1.3 Deals by Stage of Development and Deal Value 141
7.1.4 Deals by Molecule Type, Molecular Target and Deal Value 142
7.1.5 Table for Licensing Deals with Disclosed Deal Value 143
7.2 Co-development Deals 154
7.2.1 Deals by Region, Deal Value and Year 154
7.2.2 Deals by Indication and Deal Value 156
7.2.3 Deals by Stage of Development and Deal Value 157
7.2.4 Deals by Molecule Type, Molecular Target and Deal Value 158
7.2.5 Table for Co-development Deals with Disclosed Deal Value 159
8 Appendix 164
8.1 References 164
8.2 Figures of All Clinical Stage Pipeline Products 177
8.3 Abbreviations 203
8.4 Disease List 205
8.5 Methodology 206
8.5.1 Coverage 206
8.5.2 Secondary Research 207
8.5.3 Market Size and Revenue Forecasts 207
8.5.4 Pipeline Analysis 207
8.5.5 Competitive Landscape 208
8.6 Contact Us 209
8.7 Disclaimer 209
1.1 List of Tables
Table 1: Cancer Immunotherapies Drugs Market, Global, Breast Cancer Histopathological and Molecular Classification, 2018 13
Table 2: Cancer Immunotherapies Drugs Market, 7MM, Epidemiology of Key Indications, 2016 37
Table 3: Cancer Immunotherapies Drugs Market, US, Breast Cancer Stage at Diagnosis and Five-Year Relative Survival Rate (%), 2016 42
Table 4: Cancer Immunotherapies Drugs Market, US, Leukemia Subtype and Five-Year Survival Rates (%), 2016 43
Table 5: Cancer Immunotherapies Drugs Market, US, Lymphoma Subtype and Survival Rates (%), 2016 44
Table 6: Cancer Immunotherapies Drugs Market, US, Cutaneous Melanoma Stage and Survival Rates (%), 2016 44
Table 7: Cancer Immunotherapies Drugs Market, US, NSCLC Stage at Diagnosis and Five-Year Relative Survival (%), 2017 46
Table 8: Cancer Immunotherapies Drugs Market, Global, Approved Cancer Immunotherapies Indications for Revlimid, 2018 50
Table 9: Cancer Immunotherapies Drugs Market, Global, Approved Cancer Immunotherapies Indications for Opdivo, 2018 53
Table 10: Cancer Immunotherapies Drugs Market, Global, Approved Cancer Immunotherapies Indications for Keytruda, 2018 55
Table 11: Cancer Immunotherapies Drugs Market, Global, Approved Cancer Immunotherapies Indications for Tecentriq, 2018 58
Table 12: Cancer Immunotherapies Drugs Market, Global, Approved Cancer Immunotherapies Indications for Darzalex, 2018 59
Table 13: Cancer Immunotherapies Drugs Market, Global, Approved Cancer Immunotherapies Indications Imfinzi, 2018 61
Table 14: Cancer Immunotherapies Drugs Market, Global, Approved Cancer Immunotherapies Indications for Gardasil, 2018 63
Table 15: Cancer Immunotherapies Drugs Market, Global, Approved Cancer Immunotherapies Indications for Pomalyst, 2018 65
Table 16: Cancer Immunotherapies Drugs Market, Global, Approved Cancer Immunotherapies Indications for Yescarta, 2018 67
Table 17: Cancer Immunotherapies Drugs Market, Global, Approved Cancer Immunotherapies Indications for Gazyva, 2018 68
Table 18: Cancer Immunotherapies Drugs Market, Global, Approved Cancer Immunotherapies Indications for Yervoy, 2018 70
Table 19: Cancer Immunotherapies Drugs Market, Global, Approved Cancer Immunotherapies Indications for Rituxan, 2018 71
Table 20: Cancer Immunotherapies Drugs Market, Global, Approved Cancer Immunotherapies Indications for Kymriah, 2018 73
Table 21: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for Key Products ($bn), 2017-2024 110
Table 22: Cancer Immunotherapies Drugs Market, Global, Forecast Revenue by Company, 2017-2024 120
Table 23: Cancer Immunotherapies Drugs Market, Global, Licensing Deals, 2006-2018 143
Table 24: Cancer Immunotherapies Drugs Market, Global, Co-development Deals, 2006-2018 159
1.2 List of Figures
Figure 1: Cancer Immunotherapies Drugs Market, Global, Frequency of Molecular Aberrations in Non-Small Cell Lung Cancer (%), 2018 34
Figure 2: Cancer Immunotherapies Drugs Market, 7MM, Epidemiology Patterns for Breast Cancer, 2016-2023 38
Figure 3: Cancer Immunotherapies Drugs Market, 7MM, Epidemiology Patterns for Leukemia, 2016-2023 39
Figure 4: Cancer Immunotherapies Drugs Market, 7MM, Epidemiology Patterns for Lymphoma, 2016-2023 40
Figure 5: Cancer Immunotherapies Drugs Market, 7MM, Epidemiology Patterns for Cutaneous Melanoma, 2016-2023 41
Figure 6: Cancer Immunotherapies Drugs Market, 7MM, Epidemiology Patterns for NSCLC, 2016-2023 42
Figure 7: Cancer Immunotherapies Drugs Market, Global, Key Marketed Products and Approved Indications, 2018 50
Figure 8: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Revlimid ($bn), 2006-2024 52
Figure 9: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Opdivo ($bn), 2014-2024 55
Figure 10: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Keytruda ($bn), 2014-2024 57
Figure 11: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Tecentriq ($bn), 2016-2024 59
Figure 12: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Darzalex ($bn), 2015-2024 60
Figure 13: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Imfinzi ($bn), 2017-2024 62
Figure 14: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Gardasil ($bn), 2006-2024 64
Figure 15: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Pomalyst ($bn), 2013-2024 66
Figure 16: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Yescarta ($bn), 2018-2024 68
Figure 17: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Gazyva ($bn), 2013-2024 69
Figure 18: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Yervoy ($bn), 2011-2024 71
Figure 19: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Rituxan ($bn), 2006-2024 73
Figure 20: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Kymriah ($bn), 2017-2024 75
Figure 21: Cancer Immunotherapies Drugs Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2018 76
Figure 22: Cancer Immunotherapies Drugs Market, Global, Cancer Immunotherapies Pipeline by Stage of Development, Molecule Type and Program Type, 2018 77
Figure 23: Cancer Immunotherapies Drugs Market, Global, Pipeline for Key Indications by Stage of Development, 2018 78
Figure 24: Cancer Immunotherapies Drugs Market, Global, Pipeline for Key Indications by Molecule Type, 2018 79
Figure 25: Cancer Immunotherapies Drugs Market, Global, Cancer Immunotherapies Pipeline by Molecular Target, 2018 81
Figure 26: Cancer Immunotherapies Drugs Market, Global, Pipeline for Key Indications by Molecular Target, 2018 82
Figure 27: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Failure Rates and Overall Clinical Trial Attrition Rate by Stage of Development (%), 2006-2018 83
Figure 28: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Failure Rates and Overall Clinical Trial Attrition Rates by Stage of Development and Indication (%), 2006-2018 84
Figure 29: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Failure Rates and Overall Clinical Trial Attrition Rates by Stage of Development and Molecule Type (%), 2006-2018 85
Figure 30: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Failure Rates and Overall Clinical Trial Attrition Rates by Stage of Development and Molecular Target (%), 2006-2018 86
Figure 31: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Duration by Stage of Development (months), 2006-2018 87
Figure 32: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006-2018 88
Figure 33: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006-2018 89
Figure 34: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006-2018 90
Figure 35: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Size by Stage of Development (participants), 2006-2018 91
Figure 36: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Size by Stage of Development and Indication (participants), 2006-2018 92
Figure 37: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Size by Stage of Development and Molecule Type (participants), 2006-2018 93
Figure 38: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Size by Stage of Development and Molecular Target (participants), 2006-2018 94
Figure 39: Cancer Immunotherapies Drugs Market, Global, Clinical Program Size by Stage of Development (participants), 2006-2018 95
Figure 40: Cancer Immunotherapies Drugs Market, Global, Clinical Program Size by Stage of Development and Indication (participants), 2006-2018 96
Figure 41: Cancer Immunotherapies Drugs Market, Global, Clinical Program Size by Stage of Development and Molecule Type (participants), 2006-2018 97
Figure 42: Cancer Immunotherapies Drugs Market, Global, Clinical Program Size by Stage of Development and Molecular Target (participants), 2006-2018 98
Figure 43: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for Lisocabtagene maraleucel ($m), 2018-2024 100
Figure 44: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for Durvalumab plus Tremelimumab ($m), 2018-2024 101
Figure 45: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for Tremelimumab ($m), 2018-2024 103
Figure 46: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for Cemiplimab ($m), 2019-2024 104
Figure 47: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for Epacadostat ($bn), 2020-2024 105
Figure 48: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for Axalimogene filolisbac ($m), 2020-2024 107
Figure 49: Cancer Immunotherapies Drugs Market, Global, Market Size ($bn), 2017-2024 108
Figure 50: Cancer Immunotherapies Drugs Market, Global, Key Products Market Share, 2017-2024 112
Figure 51: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for Premium and Generic Products ($bn), 2017-2024 113
Figure 52: Cancer Immunotherapies Market, Global, Annual Revenue Forecast for Immune Checkpoint Proteins ($bn), 2017-2024 114
Figure 53: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for Tumor Associated Antigens ($bn), 2017-2024 116
Figure 54: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for Cytokine Signaling ($bn), 2017-2024 117
Figure 55: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for HPV Vaccines ($bn), 2017-2024 118
Global 5-Fluorouracil Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 76
The global 5-Fluorouracil market was valued at US$ 283 million in 2023 and is anticipated to reach US$ 487.9 million by 2030, witnessing a CAGR of 4.3% during The forecast period 2024-2030.
North American market for 5-Fluorouracil is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030.
Asia-Pacific market for 5-Fluorouracil is estimated to increase from $ million in 2023 to reach $ million by ......
Global Carboplatin Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 79
The global Carboplatin market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030.
North American market for Carboplatin is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030.
Asia-Pacific market for Carboplatin is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % d......
Global Neutropenia Drugs Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 96
The global Neutropenia Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estimated to increa......
Global Small Molecule Cancer Drug Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 85
The global Small Molecule Cancer Drug market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estimated ......
Global Capecitabine Market Research Report 2024
Published: 08-Jan-2024 Price: US 2900 Onwards Pages: 80
Capecitabine is an orally-administered chemotherapeutic agent used in The treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, which is enzymatically converted to fluorouracil (antimetabolite) in The tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
Common side effects include abdominal pain, vomiting, diarrhea, weakness, and rashes. Other severe side effects include blood clotting problems, allergic reactions, heart problems, and low blo......
Global Oxaliplatin Market Research Report 2024
Published: 08-Jan-2024 Price: US 2900 Onwards Pages: 104
Oxaliplatin is a platinum-based anticancer drug with colorless or nearly colorless transparent liquid. It is often used for metastatic colorectal cancer treatment or adjuvant therapy The third stage colon cancer after resecting primary tumor completely.
In this report, only The finished drug is covered, exclude API.
The global Oxaliplatin market was valued at US$ 897.5 million in 2023 and is anticipated to reach US$ 1641.5 million by 2030, witnessing a CAGR of 8.9% duri......
Global Cancer Treatment Drugs Market Growth 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 158
According to our LPI (LP Information) latest study, the global Cancer Treatment Drugs market size was valued at US$ 174990 million in 2023. With growing demand in downstream market, the Cancer Treatment Drugs is forecast to a readjusted size of US$ 322540 million by 2030 with a CAGR of 9.1% during review period.
The research report highlights the growth potential of the global Cancer Treatment Drugs market. Cancer Treatment Drugs are expected to show stable growth in the future market. H......
Global Capecitabine Market Growth 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 93
According to our LPI (LP Information) latest study, the global Capecitabine market size was valued at US$ 1003.9 million in 2023. With growing demand in downstream market, the Capecitabine is forecast to a readjusted size of US$ 975.1 million by 2030 with a CAGR of -0.4% during review period.
The research report highlights the growth potential of the global Capecitabine market. Capecitabine are expected to show stable growth in the future market. However, product differentiation, reducin......
Global Methotrexate Market Growth 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 95
According to our LPI (LP Information) latest study, the global Methotrexate market size was valued at US$ 506 million in 2023. With growing demand in downstream market, the Methotrexate is forecast to a readjusted size of US$ 613.9 million by 2030 with a CAGR of 2.8% during review period.
The research report highlights the growth potential of the global Methotrexate market. Methotrexate are expected to show stable growth in the future market. However, product differentiation, reducing co......
SERVICES
Value for Money
We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
Ever Growing Inventory
Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
One Stop Solution
Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
Dedicated Client Engagement
Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
Saving Time and Efforts
Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
Payment Flexibility
Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
Post-Purchase Research Support
Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements.
Subscription Offers & Packages (Get in touch with us for more details -
[email protected] / +1 888 391 5441 )
- Ad Hoc
-
- Pay - as - you - go / Bucket Subscriptions
- Fixed Cost for #of reports
- Customize / Personalize as per your needs
